KR20230092938A - 바이러스 단백질 서열로부터의 전사 활성 복합체 표적화 암 약물 - Google Patents

바이러스 단백질 서열로부터의 전사 활성 복합체 표적화 암 약물 Download PDF

Info

Publication number
KR20230092938A
KR20230092938A KR1020237015229A KR20237015229A KR20230092938A KR 20230092938 A KR20230092938 A KR 20230092938A KR 1020237015229 A KR1020237015229 A KR 1020237015229A KR 20237015229 A KR20237015229 A KR 20237015229A KR 20230092938 A KR20230092938 A KR 20230092938A
Authority
KR
South Korea
Prior art keywords
peptide
cell
polypeptide
myc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015229A
Other languages
English (en)
Korean (ko)
Inventor
요시히로 이주미야
미치코 시모다
Original Assignee
더 리전츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20230092938A publication Critical patent/KR20230092938A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237015229A 2020-10-21 2021-10-21 바이러스 단백질 서열로부터의 전사 활성 복합체 표적화 암 약물 Pending KR20230092938A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063094766P 2020-10-21 2020-10-21
US63/094,766 2020-10-21
US202163152959P 2021-02-24 2021-02-24
US63/152,959 2021-02-24
US202163222697P 2021-07-16 2021-07-16
US63/222,697 2021-07-16
PCT/US2021/055979 WO2022087221A1 (en) 2020-10-21 2021-10-21 Transcription active complex targeting cancer drug from viral protein sequence

Publications (1)

Publication Number Publication Date
KR20230092938A true KR20230092938A (ko) 2023-06-26

Family

ID=81290054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015229A Pending KR20230092938A (ko) 2020-10-21 2021-10-21 바이러스 단백질 서열로부터의 전사 활성 복합체 표적화 암 약물

Country Status (7)

Country Link
US (1) US12528840B2 (https=)
EP (1) EP4232061A4 (https=)
JP (1) JP2023549476A (https=)
KR (1) KR20230092938A (https=)
AU (1) AU2021365153A1 (https=)
CA (1) CA3195795A1 (https=)
WO (1) WO2022087221A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4616864A1 (en) * 2024-03-11 2025-09-17 Peptomyc, S.L. Compound for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
WO2014127148A1 (en) 2013-02-14 2014-08-21 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
WO2019108134A1 (en) 2017-11-29 2019-06-06 Agency For Science, Technology And Research Chimeric molecule for targeting c-myc in cells

Also Published As

Publication number Publication date
JP2023549476A (ja) 2023-11-27
CA3195795A1 (en) 2022-04-28
US12528840B2 (en) 2026-01-20
EP4232061A4 (en) 2024-10-16
AU2021365153A1 (en) 2023-05-25
AU2021365153A9 (en) 2024-10-24
EP4232061A1 (en) 2023-08-30
WO2022087221A1 (en) 2022-04-28
US20230382953A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US11628201B2 (en) Use of toll-like receptor agonist for treating cancer
JP6671069B2 (ja) 炎症性疾患の予防又は治療剤
TW201900212A (zh) 使用可溶性ｃｄ２４治療癌症療法中之免疫相關不良事件的方法
WO2018009528A1 (en) Combination cancer immunotherapies with arginine depletion agents
JP6918005B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
US20250064889A1 (en) Trpv6 inhibitors and combination therapies for treating cancers
US12528840B2 (en) Transcription active complex targeting cancer drug from viral protein sequence
JP2026026192A (ja) Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物
TW202321458A (zh) 新穎抗體組合及其用途
KR20200143385A (ko) Mospd2와, t 세포 또는 nk 세포 특이적 분자에 대한 2중 특이적 항체
CA2738605A1 (en) Composition and method for treatment of preterm labor
CN116917337A (zh) 来自病毒蛋白序列的转录活性复合物靶向癌症药物
CN108948203A (zh) 抗pd-1单克隆抗体及其制备方法和应用
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
US20160082104A1 (en) Methods and Compositions for the Treatment of Proliferative and Pathogenic Diseases
EP4538285A1 (en) Pd-1 variant and use thereof
CN117192118B (zh) 一种抗cldn 18.2和cd47的双特异性抗体治疗疾病的用途
US20260034229A1 (en) Antibody-targeted enzymatic chemoprotection
EP4722248A1 (en) Bispecific antibody that recognizes ccr8 as antigen
WO2022089557A1 (zh) Itpripl1的调节剂在制备调节免疫反应或抗肿瘤的药物中的用途
HK40093016A (zh) 经修饰的猪胰腺弹性蛋白酶蛋白
US20210009707A1 (en) Methods and Compositions for the Treatment of Myelodysplastic Syndrome
WO2009014560A1 (en) Methods and compositions for the treatment of pathogenic deseases
EA041126B1 (ru) Антитела и полипептиды, направленные против cd127

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241007

Comment text: Request for Examination of Application